Chemi-Verse BTK Kinase Assay Kit

Catalog #
82298
$535 *
Size: 96 reactions
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The Chemi-Verse™ BTK Kinase Assay Kit is designed to measure BTK (Bruton’s tyrosine kinase) kinase activity for screening and profiling applications using ADP-Glo™ as a detection reagent. The assay kit comes in a convenient 96-well format, with enough purified BTK, kinase substrate, ATP, and kinase assay buffer for 100 enzyme reactions.

Synonyms
Tyrosine-protein kinase BTK, Agammaglobulinemia tyrosine kinase (ATK), B-cell progenitor kinase (BPK), Bruton tyrosine kinase, AGMX1, ATK, BPK
Product Info
Storage and Usage
Citations
Assay Kit Format
Luminescent
Materials Required But Not Supplied
  • ADP-Glo™ Kinase Assay (Promega #V6930)
  • DTT (Dithiothreitol), 1M, optional
  • Microplate reader capable of reading luminescence
  • Adjustable micropipettor and sterile tips
  • 30°C incubator
Format
Catalog # Name Amount Storage
40405 BTK, GST-His-Tag* 20 µg -80°C
79334 5x Kinase Buffer 1 1.5 ml -20°C
79686 500 µM ATP 50 µl -20°C
40217  Poly-(Glu, Tyr 4:1) (10 mg/ml) 50 µl -20°C
79696 White 96-well plate 1 Room Temp

*The concentration of the protein is lot-specific and will be indicated on the tube.

UniProt #
Q06187
Background

Bruton’s tyrosine kinase or BTK, is a non-receptor kinase protein found in hematopoietic and plasma cells. It is involved in functionality, maturation, and apoptosis of B cells, in addition to regulating signals in the MAPK (mitogen-activated protein kinase), PI3K (phosphoinositide 3-kinase) and NF-κB (nuclear factor kappa B) pathways. The BTK pathway has implications for a number of autoimmune disorders including isolated growth hormone deficiency type III and rheumatoid arthritis. BTK inhibitors have been used in the treatment of inflammatory diseases and hematological disorders including cancer. For instance, Ibrutinib (also known as PCI-32765), is used in the clinic for the treatment of CLL (chronic lymphocytic leukemia), MCL (mantle cell lymphoma) and GvHD (graft versus host disease) and other diseases. However, low-selectivity BTK inhibitors have severe side effects, so further refinement is necessary. Development of highly selective BTK inhibitors will lead to greater benefits in the treatment of cancer and immune diseases.

References

Rawlings D., et al., 1993 Science 261(5519):358-361.
Alrouji M., et al., 2023 Scientific Reports 13: 17684.